A new 24-month clinical trial has found that vaping has no negative health impact on former smokers who had been vaping for two years.

The study, by UKVIA member Fontem Ventures, examined 209 volunteer former-smokers using an e-cigarette for 24 months, and monitored any adverse effects, as well as lung function, electrocardiogram results, and exposure to nicotine and tobacco constituents.

During the clinical trial, there were no serious safety concerns or medically concerning findings identified among the participants. The use of the vaping products was also associated with a reduction in nicotine withdrawal symptoms and no increase in body weight.

Tanvir Walele, Director of Scientific Affairs at Fontem Ventures, the owner of e-cigarette brand blu said: “This study shows that after two years of continual e-cigarette use, there were no signs of serious health complications in smokers. Governments and policy-makers should ensure that regulatory frameworks reflect this emerging scientific consensus, as more long term research demonstrates the safety profile of e-cigarettes.

This research suggests we need e-cigarette regulation that is not modelled on tobacco product regulation, but encourages innovation and compliance with robust product quality, manufacturing and safety standards.”

A UKVIA spokesperson welcomed the study: “this is yet more scientific support for what many in the public health community already know; vaping is vastly safer than smoking and an effective tool for those smokers looking to make the life-changing decision to switch to vaping.

You can read the full study here.